Ginkgo Bioworks Holdings EPS History: Annual & Quarterly (DNA)
Ginkgo Bioworks Holdings's diluted EPS was -$5.64 for fiscal 2025.
View full Ginkgo Bioworks Holdings company overviewGinkgo Bioworks Holdings annual diluted eps history
| Fiscal year | Period ended | Diluted EPS | Basic EPS | Change | Growth |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | -$5.64 | -$5.64 | $4.90 | — |
| 2024 | 2024-12-31 | -$10.54 | -$10.54 | $7.83 | — |
| 2023 | 2023-12-31 | -$18.37 | -$18.37 | $31.83 | — |
| 2022 | 2022-12-31 | -$50.20 | -$50.15 | $88,909.80 | — |
| 2021 | 2021-12-31 | -$88,960.00 | -$86,400.00 | -$82,560.00 | — |
| 2020 | 2020-12-31 | -$6,400.00 | -$6,400.00 | $0.00 | — |
| 2019 | 2019-12-31 | -$6,400.00 | -$6,400.00 | — | — |
Ginkgo Bioworks Holdings quarterly diluted eps
| Fiscal quarter | Period ended | Diluted EPS | Basic EPS | Change | YoY change |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | -$0.75 | -$0.75 | $0.35 | — |
| Q1 2026 | 2026-03-31 | -$1.39 | -$1.39 | $0.29 | — |
| Q3 2025 | 2025-09-30 | -$1.45 | -$1.45 | -$0.37 | — |
| Q2 2025 | 2025-06-30 | -$1.10 | -$1.10 | $3.13 | — |
| Q1 2025 | 2025-03-31 | -$1.68 | -$1.68 | $1.64 | — |
| Q3 2024 | 2024-09-30 | -$1.08 | -$1.08 | $5.13 | — |
| Q2 2024 | 2024-06-30 | -$4.23 | -$4.23 | $5,755.77 | — |
| Q1 2024 | 2024-03-31 | -$3.32 | -$3.31 | $7,036.68 | — |
| Q3 2023 | 2023-09-30 | -$6.21 | -$6.21 | $26,233.79 | — |
| Q2 2023 | 2023-06-30 | -$5,760.00 | -$5,760.00 | $20,480.00 | — |
| Q1 2023 | 2023-03-31 | -$7,040.00 | -$7,040.00 | $16,640.00 | — |
| Q3 2022 | 2022-09-30 | -$26,240.00 | -$26,240.00 | -$21,120.00 | — |
| Q2 2022 | 2022-06-30 | -$26,240.00 | -$26,240.00 | -$23,680.00 | — |
| Q1 2022 | 2022-03-31 | -$23,680.00 | -$23,680.00 | — | — |
| Q3 2021 | 2021-09-30 | -$5,120.00 | -$5,120.00 | — | — |
| Q2 2021 | 2021-06-30 | -$2,560.00 | -$2,560.00 | — | — |
Ginkgo Bioworks Holdings diluted eps trends
Over the last five fiscal years, Ginkgo Bioworks Holdings's diluted eps increased from -$6,400.00 to -$5.64, a change of $6,394.36. The latest reported quarter, Q2 2026, shows -$0.75.
What earnings per share (EPS) means
Earnings per share (EPS) shows how much profit or loss is attributable to each common share. Diluted EPS includes the potential effect of convertible securities, options, and other instruments that could increase the share count, while basic EPS uses the weighted-average common shares actually outstanding.
SEC-reported diluted and basic EPS
TickerStat displays diluted and basic earnings per share from SEC filings. Historical EPS values are adjusted to the current share basis when SEC-reported stock-split conversion ratios are available; they are not analyst estimates or earnings forecasts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ginkgo Bioworks Holdings source filings ↗Community posts
Ginkgo joins a federally backed RNA-manufacturing project worth up to $17.5 million
Ginkgo Bioworks ($DNA) received a subcontract worth up to $17.5 million to participate in an ARPA-H program focused on RNA manufacturing. Waterfall Scientific is the prime contractor. The project, called ESCALATOR, is intended to combine co ...